BriaCell Therapeutics Corp., announced that its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.
[BriaCell Therapeutics Corp.]
6445212
AAAAAAAA
items
1
apa
0
default
asc
1
173744
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
